Views & Analysis | Perspectives on pharma industry issues

Patients

A hand grabs and breaks a DNA chain to represent biohacking

Why biohackers are ditching vague health metrics

Precision diagnostics enable targeted therapeutics.

Market Access

Anglonordic Life Science 2026: A focus on execution

The latest Anglonordic Life Science Conference on 23rd April exhibited a cautious optimism.

Digital

12 Questions With Navdeep "Navi" Chadha

Navdeep "Navi" Chadha is co-founder & CTO of Axtria, a global provider of AI-powered data analytics and cloud software for the life sciences industry.

R&D

Podcast interview with Boyang Wang, the founder of Immortal Dragons

Why everyone should care about longevity, with Boyang Wang

In today’s episode of the pharmaphorum podcast, host Jonah Comstock speaks with Boyang Wang, the founder of Immortal Dragons.

Patients

Hands in a circle point to the middle where EU stars are, blue background

Stronger together: The future of psychiatry in a changing Eu...

Mental disorders account for a significant share of economic cost across EU Member States and the United Kingdom.

Views & Analysis

Osteoporosis treatment options - down to the bare bones

It is World Osteoporosis Day this month, and Ben Hargreaves takes a look at what treatment options look like for patients living with the disease.

Digital

Reuters: Pharma 2022

The Reuters Pharma 2022 event is live in Nice and pharmaphorum is on site to provide readers with rolling coverage of the speakers and concepts as it unfolds over the next few days.

Patients

Building agile partner relationships at a vaccine-focused bi...

In this episode of the pharmaphorum podcast series, Dr Paul Tunnah chats with Jeff Baxter, CEO of VBI Vaccines and Lee Taurman, executive vice president full service commercial at Syneos Health.

Sales & Marketing

pharmaphorum podcast Episode 257, John Holodnak, Occam

A philosophical look at market turn in the Age of AI, with J...

John Holodnak, co-founder of Occam, discusses how AI is beginning to reshape career paths across life sciences.

Sales & Marketing

Changing Faces: Agency, consultancy, and investor, March 202...

March saw a handful of noteworthy hires in the agency, consultancy, and investor spaces.

Digital

12 Questions With Navdeep "Navi" Chadha

Navdeep "Navi" Chadha is co-founder & CTO of Axtria, a global provider of AI-powered data analytics and cloud software for the life sciences industry.

Digital

The augmented marketer: Fusing AI and human expertise in lif...

Predictive AI is not replacing human expertise, but augmenting it.

Market Access

Anglonordic Life Science 2026: A focus on execution

The latest Anglonordic Life Science Conference on 23rd April exhibited a cautious optimism.

Market Access

Health, growth & renewal: ABPI 2026 looks to UK’s future

The Association of the British Pharmaceutical Industry (ABPI)'s flagship annual conference took place on Thursday, 23rd April.

Oncology

From promise to practice: What must happen next for genetic ...

The systems needed to deliver GBT testing consistently across the NHS are still evolving to keep pace with these scientific advances.

Oncology

LSX2026: Addressing adult eye cancer, with Roi Raz

Roi Raz, CEO of ReBio Pharma, discusses injectable, bioresorbable sustained release delivery for ophthalmic therapeutics at LSX 2026.

Oncology

From preclinical toxicology to clinical safety: The path for...

Successfully navigating the process for drugs with a higher risk-benefit ratio requires a tailored non-clinical programme design.

Patients

Why biohackers are ditching vague health metrics

Precision diagnostics enable targeted therapeutics.

Patients

Stronger together: The future of psychiatry in a changing Eu...

Mental disorders account for a significant share of economic cost across EU Member States and the United Kingdom.

Patients

More than a discount: How intelligent copay programmes are r...

Brian Laird explains a more dynamic, data-driven approach to copay is redefining affordability, creating a new standard for balancing patient support.

Why biohackers are ditching vague health metrics

Anglonordic Life Science 2026: A focus on execution

12 Questions With Navdeep "Navi" Chadha

Why everyone should care about longevity, with Boyang Wang

Stronger together: The future of psychiatry in a changing Eu...

Osteoporosis treatment options - down to the bare bones

Reuters: Pharma 2022

Building agile partner relationships at a vaccine-focused bi...

A philosophical look at market turn in the Age of AI, with J...

Changing Faces: Agency, consultancy, and investor, March 202...

12 Questions With Navdeep "Navi" Chadha

The augmented marketer: Fusing AI and human expertise in lif...

Anglonordic Life Science 2026: A focus on execution

Health, growth & renewal: ABPI 2026 looks to UK’s future

From promise to practice: What must happen next for genetic ...

LSX2026: Addressing adult eye cancer, with Roi Raz

From preclinical toxicology to clinical safety: The path for...

Why biohackers are ditching vague health metrics

Stronger together: The future of psychiatry in a changing Eu...

More than a discount: How intelligent copay programmes are r...

Why everyone should care about longevity, with Boyang Wang

Beyond proof of concept: Alzheimer’s and the next chapter of...

Changing Faces: Board of Directors and Advisory Boards, Marc...

Lilly inflates US facility investment spending by $4.5bn

Discover a new era of healthcare panel engagement: Grounded ...

Sales & Marketing

Digital

Market Access

Editor's Picks

Oncology

Patients

R&D

Editor's Picks